Efficacy
DISEASE PROGRESSION, DISEASE, BEST
Among the 40 patients, 23 (57.5%) achieved disease control (NED, CR, PR, and stable disease) after 6 months of treatment, whereas 17 patients (42.5%) discontinued treatment because of disease progression within the first 6 months. A total of 16 patients (40.0%) received the MEMMAT treatment for at least 1 year. Three patients had a complete resection of their relapse and remained with NED thereafter (7.5%). Best response was CR in 6 patients (15.0%), PR in 9 patients (22.5%), and stable disease in 5 patients (12.5%). Objective response rate, defined as ongoing NED after complete resection, CR, or PR, was 45%.Median follow-up time was 40.5 months (range, 1.3-94.9 months), and mean (SD) PFS at both 3 and 5 years was both 24.6% (7.9%). Mean (SD) OS was 43.6% (8.5%) at 3 years and 22.6% (8.8%) at 5 years. Median PFS and OS were 8.5 months (range, 1.7-15.4 months) and 25.5 months (range, 10.9-40.0 months), respectively (